Article Text

PDF
Correlation of autoantibodies and CD5+ B cells in ocular adnexal marginal zone B cell lymphomas
  1. T Kubota1,
  2. S Moritani2,
  3. T Yoshino3,
  4. H Nagai4,
  5. H Terasaki5
  1. 1
    Department of Ophthalmology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
  2. 2
    Department of Pathology, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
  3. 3
    Department of Pathology, Okayama University Graduate School of Medical, Dentistry and Pharmaceutical Science, Okayama, Japan
  4. 4
    Department of Internal Medicine, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan
  5. 5
    Department of Ophthalmology, Nagoya University Medical School, Nagoya, Japan
  1. Correspondence to Toshinobu Kubota, Department of Ophthalmology, National Hospital Organization, Nagoya Medical Center, 4-1-1, Sannomaru, Naka-ku, Nagoya-shi, Aichi-ken, 460-0001, Japan; ganiky{at}nnh.hosp.go.jp

Abstract

Aim: To determine the clinicopathological properties of ocular adnexal marginal zone B cell lymphomas (MZBLs) with CD5+ B cells.

Methods: This study determined the clinicopathological properties of MZBL samples from 97 patients with ocular adnexal MZBLs and searched for hallmarks of systemic autoimmunity in these patients.

Results: Two elderly female patients were found to have ocular adnexal MZBLs with CD5+ B cells; flow cytometry analysis suggested that one of these MZBLs had CD5+ B cell clonal proliferation. The levels of anti-single stranded (SS)-DNA and anti-SS-A/Ro antibodies in these two patients were significantly higher than those in controls that were matched for age, gender and disease (2/2 versus 0/14; p = 0.008) and controls without MZBL (2/2 versus 0/30; p = 0.002). The genes from the immunoglobulin heavy-chain variable region for one of the patients showed a V3-21 segment. In addition, another patient with ocular adnexal reactive lymphoid hyperplasia with CD5+ B cells also had anti-SS-DNA antibodies.

Conclusion: Patients with ocular adnexal MZBLs with CD5+ B cells may have a background of systemic conditions with CD5+ B-cell-related autoantibodies.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Ethics approval Ethics approval was obtained from the Ethics Committee at Nagoya Medical Center, Nagoya, Japan.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.